Attendees who purchased access to the 2016 Annual Meeting webcast will be sent login information on May 11.

Login for full access:

Username and password are not your MyAACR account information

Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

Conference Years:

Days Within Meeting:

Conferences:

Availability:

Participation Type:

Presentations Access:

Presentation Access:

Topic Tracks*:

Organ Site Tracks*:

  • Sort by:
  • Browse by:
<< first | < prev page: of 332 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 329 330 331 332 presentations: 1 to 25 of 8278
AACR Annual Meeting 2016 Highlights: Vision for the Future
Welcome
Jose Baselga, MD, PhD
AACR Immediate Past President
Physician-in-Chief
Memorial Sloan Kettering Cancer Center
New York, NY
Video Tribute to Vice President Biden

Introduction of Jill Biden
Sophia Lunt
Assistant Professor, Biochemistry and Molecular Biology
Michigan State University
East Lansing, Michigan
Introduction of Vice President Biden
Jill Biden
Second Lady of the United States
Vice President Biden's Address to AACR Annual Meeting 2016
Joe Biden
Vice President of the United States
from AACR Annual Meeting 2016 on April 20, 2016 12:15 PM-2:00 PM
AACR Annual Meeting 2016 Highlights: Vision for the Future
Basic mechanisms and new therapeutic combinations
Scott A. Armstrong
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 20, 2016 12:15 PM-2:00 PM
AACR Annual Meeting 2016 Highlights: Vision for the Future
Precision medicine breakthroughs
Jose Baselga
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 20, 2016 12:15 PM-2:00 PM
AACR Annual Meeting 2016 Highlights: Vision for the Future
Prevention and early detection of cancer: Challenges and opportunities
Elaine R. Mardis
Washington University School Of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 20, 2016 12:15 PM-2:00 PM
AACR Annual Meeting 2016 Highlights: Vision for the Future
Wrap-up and vision for the future
Nancy E. Davidson
University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States
from AACR Annual Meeting 2016 on April 20, 2016 12:15 PM-2:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Chairperson
Scott A. Armstrong
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Cancer genomics: A translational future
Elaine R. Mardis
Washington University School Of Medicine, Saint Louis, MO, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Targeting epigenomic dependencies in cancer
James E. Bradner
Novartis, Cambridge, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Genome editing using CRISPR-Cas systems
Feng Zhang
Massachusetts Institute of Technology, Cambridge, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
T cell recognition of human cancer
Ton Schumacher
Netherlands Cancer Inst., Amsterdam, Netherlands
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Opening Plenary-- Breakthroughs in Cancer Research: Genomics, Epigenetics, and Immunomodulation
Stem cells and cancer
Elaine Fuchs
Howard Hughes Medical Institute/Rockefeller University, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 9:30 AM-12:00 PM
Immuno-oncology Clinical Trials I
Initial report of overall survival rates from a randomized phase II trial evaluating the combination of nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma (MEL)
Michael Postow
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Padmanee Sharma
UT MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma
Matteo Carlino
Crown Princess Mary Cancer Centre, Westmead and Blacktown Hospitals, Wentworthville, Australia
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Charles G. Drake
Johns Hopkins Kimmel Comp. Cancer Center, Baltimore, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
A phase I study of an HLA-DPB1*0401-restricted T-cell receptor targeting MAGE-A3 for patients with metastatic cancer
Yong-Chen Lu
National Institutes of Health, Bethesda, MD, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Michel Sadelain
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial
F. Stephen Hodi
Dana-Farber Cancer Institute, Boston, MA, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Immuno-oncology Clinical Trials I
Discussant
Jedd D Wolchok
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 2:15 PM-4:15 PM
Precision Medicine Early Clinical Trials
Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors
Jayesh Desai
Royal Melbourne Hospital, Melbourne, Australia
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Udai Banerji
Inst. of Cancer Research, Sutton, United Kingdom
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somatic MET mutations. EORTC phase II trial 90101 "CREATE"
Patrick Schoffski
University Hospitals Leuven - Department of General Medical Oncology, Leuven, Belgium
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Discussant
Ravi Salgia
City of Hope, Duarte, CA, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Entrectinib, an oral pan-Trk, ROS1, and ALK inhibitor in TKI-naïve patients with advanced solid tumors harboring gene rearrangements: Updated phase I results
Alexander Drilon
Memorial Sloan Kettering Cancer Center, New York, NY, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
Precision Medicine Early Clinical Trials
Clinical safety and activity from a phase I study of LOXO-101, a selective TRKA/B/C inhibitor, in solid-tumor patients with NTRK gene fusions
David S Hong
MD Anderson Cancer Center, Houston, TX, United States
from AACR Annual Meeting 2016 on April 17, 2016 4:15 PM-6:00 PM
<< first | < prev page: of 332 records per page: next > | last >>
pages: 1 2 3 4 5 6 ... 329 330 331 332 presentations: 1 to 25 of 8278